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Objective. To determine the incidence, management, complications, and outcome in neonates with thrombotic events. Study
Design. We performed a retrospective study of all neonates with thrombotic events admitted to our neonatal intensive care unit
from January 2004 to July 2010. Results. Thrombotic events were identiﬁed in 32 of 4734 neonates (0.7%). Seven neonates were
managed expectantly and 25 neonates received anticoagulant treatment. Complete resolution of the clot within 3 months of age
was found in 68% (17/25) of the treated and in 86% (6/7) of the nontreated neonates. Major complications due to anticoagulant
therapy occurred in 3/25 cases (12%) and included severe hemorrhage (n = 2) and abscess at the injection site (n = 1). Conclusion.
Complete or partial clot resolution in neonatal thrombosis occurred in both the treated group and nontreated group. Randomized
controlled trials are warranted to determine the optimal management in neonatal thrombosis.
1.Introduction
Neonatal thrombotic events are often reported in low birth
weight neonates, but little is known about the natural
history. Symptomatic thrombosis can lead to life threat-
ening situations such as renal failure, superior vena cava
syndrome [1], heart failure [2], and systemic or lung
embolism [3]. However, most neonates with thrombosis are
asymptomatic and thrombotic events which are often related
to indwelling catheters, may be detected by coincidence
during routine ultrasound examination [4, 5]. Management
options in neonatal thrombosis include a “wait-and-see”
policy (expectant management), medical treatment with
anticoagulants, or surgery. No randomized trials have been
performed in neonates to determine the optimal treatment
and consensus management guidelines are not available.
Whether medical or surgical treatment is indicated in
neonates with thrombotic events remains controversial. The
majority of recommendations in the literature are based on
uncontrolled studies, small case series, in vitro experiments,
or extrapolation of study data performed in the adult and
pediatric population [6].
Despite the limited evidence on the safety and eﬃcacy of
anticoagulant treatment in preterm neonates, low molecular
weight heparin (LMWH) is increasingly advocated for
numerous clinical indications. However, although serious
adverse eﬀects associated with anticoagulant treatment are
reported to be rare, several major complications have
recentlybeen described [7–9]. Data on the safety and eﬃcacy
of LMWH in neonates, and in particular in extremely low
birth weight (ELBW) neonates, is scarce and based on a
handful of case series. The aim of this study is to determine2 International Journal of Pediatrics
Table 1: Baseline and clinical characteristics of 32 neonates with neonatal thrombosis.
Treatment group (n = 25) “Wait-and-see” group (n = 7) Total (n = 32)
Female gender, n (%) 15 (60) 4 (57) 19 (59)
Gestational age (weeks)∗ 30 (27–38) 28 (25–36) 29 (27–38)
<32, n 15 5 20
32   37, n 21 3
>37, n 81 9
Birthweight (g)∗ 1256 (817–3300) 938 (734–2735) 1145 (789–3230)
<1000, n 84 1 2
1000   1500, n 61 7
>1500, n 11 2 13
UC, n (%) 18/23 (78) 5 (71) 23/30 (77)
PICC, n (%) 14/22 (64) 4 (86) 16/30 (53)
Either UC or PICC, n (%) 22/23 (96) 7 (100) 29/30 (97)
Platelet transfusionsa n (%) 11/21 (52) 2 (29) 13/26 (50)
∗Data presented as median (interquartile range (IQR)).
aDuring total hospital stay.
the incidence, management, complications, and outcome in
neonates with thrombotic events detected at our centre.
2. Methods
We performed a retrospective chart review of all neonates
with thrombotic events detected at our tertiary university
neonatal intensive care centre between January 2004 and
July 2010. The data on patients included in this study
were derived from dedicated database from our neona-
tology department and pediatric cardiology department.
The medical charts of all neonates with thrombotic events
were reviewed to determine treatment, complications, and
outcome. Ethical approval and informed consent is not
needed for this type of study in The Netherlands.
The presence of thrombosis was determined by ultra-
sonography performed by a radiologist and echocardiogra-
phy performed by a pediatric cardiologist. Thrombosis was
deﬁned as a persistent echodense structure within the heart
or a vessel, observed in two dimensions. During the study
period, no management guidelines for thrombotic events in
neonates were available at our department. Final decision in
termsoftreatmentandmanagementwaslefttothejudgment
of the attending neonatologist.
Criteria for ultrasound examination included persistent
thrombocytopenia, ongoing sepsis, or catheter obstruction.
The following perinatal data were recorded: gestational
age at birth, birth weight, gender, sepsis, presence of umbil-
ical catheter (UC) or peripherally inserted central catheter
(PICC), thrombocytopenia, number of platelet transfusions,
age at onset of thrombotic event, localization of thrombus,
neonatal mortality, and complications associated with the
thrombotic event and with the management.
3. Results
During the study period, 4734 neonates were admitted
to our neonatal intensive care unit (NICU). Thirty-two
cases (0.7%) of neonatal thrombosis were identiﬁed. The
baseline characteristics of the study population are listed
in Table 1. The majority were neonates with a gestational
age at birth <32wk (63%, 20/32) or with a very low
b i r t hw e i g h t( <1500g) (59%, 19/32). Most neonates (97%,
29/30) had an UC or PICC line prior to or at the time of
detectionofthethromboticevent.Noneoftheneonateswith
thrombotic events had signs of renal failure, superior vena
cava syndrome, heart failure, or systemic or lung embolism.
Details on the time, size, localization, and management
of the thrombotic events are presented in Table 2.T h em a i n
indication for diagnostic evaluation for thrombotic events
was persistent thrombocytopenia (53%, 17/32). Median
length and width of the thrombi were 5.3mm (interquartile
range(IQR)2.1–7.8)and2.7mm(IQR2.0–5.0),respectively.
Most thrombotic events were due to intracardiac right atrial
thrombi (47%, 15/32).
The majority of neonates (78%, 25/32) were managed
with anticoagulant therapy including Tinzaparin (n = 20),
Nadroparin (n=3), Nadroparin followed by Tinzaparin (n=
1), and Nadroparin followed by Phenprocoumon (n=1).
Complications were found in three cases (12%),
all treated with subcutaneous Tinzaparin. In all three
cases, anti-FXa levels were within therapeutic range (0.5–
1.0U/mL). One extremely low birth weight (ELBW) neonate
developed a severe hematoma at the insuﬂon (small catheter
used for daily injections) injection site, which required
emergency surgical drainage. We reported this in a recent
case report [9]. Another ELBW neonate developed a large
abscess at the insuﬂon injection site, which required surgical
drainage. Lastly, one ELBW neonate developed a grade
2 intraventricular hemorrhage and a unilateral thalamic
hemorrhage 4 days after initiation of LMWH. At the time
of initiation of LMWH (at 2 weeks of age), no signs of
intracranial hemorrhage were detected on (serial) cerebral
ultrasound exams.
Seven cases with neonatal thrombosis were managed
expectantly after removal of the UC or PICC line. FollowupInternational Journal of Pediatrics 3
Table 2: Characteristics of thrombotic events, management, and outcome.
Treatment group (n = 25) “Wait-and-see” group (n = 7) Total (n = 32)
Age at onset (days)∗ 11 (6–15) 15 (10–24) 13 (7–16)
Indication for diagnostic evaluation
Thrombopenia, n 14 3 17
Ongoing Sepsis, n 42 6
Chance ﬁnding, n 31 4
Catheter obstruction, n 4— 4
Thalamusbleeding, n —1 1
Localization
Portal vein, n 2— 2
Ductus venosus, n 41 5
Heart, n 10 5 15
Iliac vein, n 1— 1
Basilical vein, n 21 3
Femoral vein, n 4— 4
Inferior vena cava, n 2— 2
Hepatic Vein, n 1— 1
Duration of treatment (days)∗ 90 (37–90) — —
Follow up ultrasound exama
Complete resolution, n (%) 17 (68) 6 (86) 23 (72)
Partial resolution, n 61 7
Unchanged, n 1— 1
Unknown, n 1— 1
Major treatment complications, n 3— 3
∗Data presented as median (interquartile range (IQR)).
aFollow up ultrasound performed within 3 months after detection of neonatal thrombosis.
with serial ultrasound exams showed complete resolution
in 6/7 cases (86%) within 2 months. In one case there was
only partial resolution of a right atrial thrombus, without
clinical relevance (length and width decreased from 2.8 by
1.5mm to 1.8 by 1.0mm). One neonate in the “wait-and-
see” policy group had a small thrombus in the right atrium
and suﬀered from enterovirus meningitis. The patient died
due to systemic and cerebral complications of enterovirus
meningitis. Complete clot resolution was observed at follow-
up ultrasound before neonatal demise. None of the other
patients suﬀered further complications or died as a result of
the thrombus.
4. Discussion
The incidence of thrombotic events in this study was 6.8 per
1000 newborns admitted to our NICU. This rate is almost
three times higher than the frequently reported incidence by
Schmidt and Andrew of 2.4 per 1000 NICU admissions [10].
Nowak-Gottl et al. reported an incidence of symptomatic
thrombosis of 5.1 per 100.000 live births in the period
from 1992 to 1994 [11]. However, when admitted neonates
with umbilical lines in situ were screened for thrombosis, a
much higher incidence rate (from 30% to 43%) was found
[12, 13]. Discordant incidences between studies may be
due to various methodological diﬀerences, including study
designs, deﬁnitions, and criteria for neonatal thrombosis.
The true incidence of thrombosis in our cohort would have
beenundoubtedly higherifroutineultrasoundexaminations
would have been preformed in all neonates with UC or PICC
lines.
In our study, neonates with thrombotic events were
managed either with medical treatment or expectantly,
depending on the judgment of the attending neonatologist.
T h er a t eo fc o m p l e t ec l o tr e s o l u t i o ni no u rs t u d yw a s
high, both in the treatment group and in the expectant
management group, without clot-related complications in
both groups. Optimal management of neonatal throm-
bosis is controversial and consensus guidelines are not
available. Management options include a “wait-and-see”
policy (expectant management), medical treatment with
anticoagulants, or surgical treatment. Recent guidelines
advise LMWH treatment in neonatal thrombosis with a total
duration of 6 weeks to 3 months [6]. However, in this study,
we found a high rate of potentially fatal complications in
the treatment group. Similar cases of major complications
have recently been reported. In a case report, Obaid et al.
described an ELBW neonate with a severe hematoma after
treatment with LMWH [8]. The neonate developed rapidly a
progressivecompartmentsyndromeatthesiteofEnoxaparin
administration with an indwelling catheter and necessitated
surgical decompression.
In a retrospective study of 16 neonates (of whom
12 were preterm) treated with LMWH, Malowany et al.4 International Journal of Pediatrics
reported minor local adverse eﬀects (indurations, bruises,
hematomas, or leakage) at the site of the indwelling subcu-
taneous catheter in 9 (56%) neonates, but also major bleed-
ings in 5 (31%) neonates including scleral haemorrhage,
gastrointestinaltractbleeding andinfectedhematoma[7].In
prospective cohort study of 62 patients, Streif et al. reported
four (6%) major bleedings, including two major hematomas
at the injection site and one intracerebral hemorrhage 3
days after initiation of therapy [14]. Four other neonates
(6%)developedminorbleedingincludinghematuria,bloody
stool, and bleeding at the local administration site. In a
retrospective study of 10 preterm neonates treated with
LMWH due to venous and arterial thrombosis, Michaels
et al. reported bleeding complications in three patients
(30%) including mild epistaxis, small subependymal hemor-
rhage, and oozing at an operative wound site [15]. Finally,
in a review article, Malowany reported a 5% incidence of
major complications associated with LMWH therapy, based
on 240 cases (53 preterm neonates, 61 term neonates, and
126 neonates that were not diﬀerentiated on gestational age)
[16].
Interestingly, all but one major complication occurred
even though anti-FXA levels did not exceed therapeutic
range which may reﬂect the diﬀerence in pro- and anticoag-
ulant determinants in preterm neonates compared to older
children. Unfortunately, pharmacokinetic data on LMWH
in preterm neonates is lacking to enhance the urgent need
for dose ﬁnding studies in preterm neonates. A lower
target range may possibly reduce the adverse event range in
neonates without compromising clot resolution.
Alternatively, thrombotic events in neonates may also
be managed expectantly. In this study, we found a high
rate of complete clot resolution (86%) in the expectant
management group. Our ﬁndings are in accordance with
several reports of spontaneous clot resolution in untreated
cases with neonatal thrombosis [17–19]. In a randomized
controlled trial comparing long-term and short-term use of
umbilical venous catheters in premature neonates, Butler-
O’Hara et al. found 24 cases (11%) of thrombosis [17].
Neonates were managed expectantly and clot resolution was
reported in all cases without thrombolytic therapy. In a
retrospective study, Bendaly et al. describe 19 neonates with
intracardiac thrombus of whom 9 were asymptomatic [18].
The majority (8/9) did not receive thrombolytic treatment
and resolution was reported in all cases. Lastly, De Godoy et
al. reported a newborn with a large cardiac thrombus in the
left ventricle causing edema and cardiac dilation [19]. At 55
days, the intracardiac thrombus had disappeared completely
without anticoagulant treatment.
In conclusion, our data does not support the routine use
of LMWH therapy in neonatal thrombotic events. However,
the results of our study should be interpreted with care
due to several methodological limitations, including the
relative small number of neonates and the retrospective
study design. Potential bias associated with retrospective
studies does not allow us to compare the outcome between
expectant management and medical treatment in our cohort
nor the rate of complications. Both LMWH therapy and
expectant management may be associated with potential
life-threateningcomplications.Whethertreatmentshouldbe
restricted to a group of neonates with large clots or speciﬁc
symptoms is not clear. Randomized controlled trials com-
paring expectant management and treatment with LMWH
are urgently needed to determine the optimal management
in neonatal thrombosis.
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